Thirty-four adults were vaccinated with 1/50 of the usual dose of meningococcal polysaccharide vaccine (1 mg of A, C, Y, and W135 polysaccharides, given intramuscularly). This dose was selected as a probe to assess B cell memory. The probe elicited meningococcal C bactericidal antibody responses in all 18 adults who had been vaccinated 4 years earlier with an investigational meningococcal A and C oligosaccharide -protein conjugate vaccine and in the majority of the 11 subjects vaccinated for the first time. In contrast, the responses of the 5 adults given a full dose of licensed polysaccharide vaccine 4 years earlier were õ1/10 of those of the other 2 groups. Thus, adults previously given a full dose of meningococcal polysaccharide vaccine show evidence of immunologic refractoriness to group C polysaccharide, whereas refractoriness is not observed after conjugate vaccination. These findings have implications for the use of meningococcal polysaccharide vaccine when the risk of disease is low.
Neisseria meningitidis remains an important cause of invaimmunologic memory could be an important second mechanism of protection, by permitting a vaccinated person with low sive bacterial disease [1] . In most industrialized countries, the vast majority of isolates causing meningococcal disease are serum concentrations of antibody to develop booster anticapsular antibody responses on encountering encapsulated meningoserogroups B or C [1, 2]. Effective meningococcal polysaccharide vaccines have been available for ú20 years but are used cocci. Meningococcal conjugate vaccines also are highly immunoinfrequently in industrialized societies [1] . The principal reasons are their poor immunogenicity in infants and toddlers õ2 genic in adults [6] . However, the magnitude of the serum antibody responses appears to be similar to that elicited by the years of age, the age groups at greatest risk of developing meningococcal disease [1] . Further, currently available vaccorresponding plain polysaccharide vaccine [6, 7] . Thus, the advantage of using a conjugate vaccine for protection against cines provide no protection against disease caused by serogroup B strains, which account for Ç40% of cases in the United meningococcal disease in adults, compared with an unconjugated polysaccharide vaccine, is uncertain. One potential adStates and the United Kingdom [1, 2].
More effective polysaccharide-protein conjugate vaccines vantage of a meningococcal conjugate vaccine in adults could be its ability to induce polysaccharide-responsive memory B for prevention of disease caused by meningococcal A and C strains are currently under development. Being thymic-depencells and resulting long-term immunologic memory. However, to date, evidence of induction of memory B cells by conjugate dent antigens, these conjugate vaccines are more immunogenic in infants and toddlers than are the plain meningococcal polyvaccination is limited to infants and toddlers and has not been observed in adults [7] . The purpose of the present study was saccharide vaccines [3, 4] . Additionally, conjugate vaccines elicit long-term immunologic memory to unconjugated meninto assess whether previous vaccination of adults with meningococcal conjugate vaccine or plain meningococcal polysacchagococcal C polysaccharide [5] , which is not observed after plain meningococcal polysaccharide vaccine [5] . Induction of ride vaccine induces memory B cells capable of responding to unconjugated meningococcal C polysaccharide.
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Methods
Presented in part: 35th annual meeting of the Infectious Diseases Society of America, San Francisco, 13 -16 September 1997 (abstract 540).
Subjects. Thirty-four healthy adults, ages 20-53 years, were to that of different doses of an investigational meningococcal A and assigned a value of 1:4, and IgG antibody concentrations õ0.6 U/ mL were assigned a value of 0.3 U/mL. Geometric means and C oligosaccharide-protein conjugate vaccine (n Å 40) or saline (n Å 10) [6] . Group 3 consisted of 18 subjects who had previously 95% confidence intervals were calculated using the log-transformed means, and SEs were computed from a one-way analysis received a dose of an investigational meningococcal A and C oligosaccharide-CRM 197 protein conjugate [6] . In this group, the of variance (ANOVA) model. Differences between each pair of groups with respect to geometric means were tested by using the antibody responses to the booster vaccination in the subjects previously given different doses of conjugate vaccine were similar.
P values from the ANOVA model. Therefore, in the present study, the data from the booster immunization in subjects previously given different doses of the conjugate vaccine were combined.
Results
The demographic characteristics of the 3 vaccine groups were similar with respect to median age at the time of the booster Clinical tolerability. Vaccination with 1/50 of the usual vaccination (40, 38, and 36 years for groups 1, 2, and 3, respecdose of polysaccharide vaccine was well tolerated, irrespective tively), sex (female: 92%, 100%, and 89%, respectively), and race of previous meningococcal vaccination status. During the 28 distribution (white: 91%, 100%, and 94%, respectively).
days of follow-up, there were no clinically significant injection- . Similarly, there was no significant increase in geometpreviously described [8] [9] [10] . The buffer used for diluting the seric mean antibody concentration in this group when measured rum samples in the anti-C assay contained 75 mM ammonium at 28 days (0.68 U/mL; P ú .5). At 28 days, only 1 subject thiocyanate, which favored the detection of high-avidity anticapsuin group 2 showed a §2-fold increase in IgG antibody concenlar antibodies over low-avidity antibodies [10] . In both the anti-A tration, and the geometric mean IgG antibody response of group and anti-C assays, bound antibody was detected by mouse mono-2 was 1/6 to 1/10 lower than those of groups 1 or 3 (P õ .01).
clonal antibody specific for human IgG (clone HP6043 [9] , proAlthough the 1-mg dose of polysaccharide vaccine was capavided by G. Carlone, CDC, Atlanta).
ble of eliciting significant increases in serum IgG antibody
Complement-mediated bactericidal antibody to N. meningitidis group C was assayed as previously described [9, 11] , with the concentrations to meningococcal C polysaccharide in most sub- IgG responses to meningococcal A polysaccharide (comparing complement source for the bactericidal assay was pooled sera obthe respective serum antibody concentrations at day 28 with tained from 3 healthy adults who had no detectable anticapsular those at time 0). For group 2, previously given the polysacchaantibody to meningococcal C and whose sera lacked intrinsic bacride vaccine, there were no responders (0 of 5). The respective tericidal activity when tested at 20% or 40%. When assaying test differences were not significant (P ú .05). sera, the complement source was used at a final concentration of Bactericidal antibody response. Respective geometric mean antibody responses of group 2 (given full dose of meningococcal polysaccharide vaccine 4 years earlier) were significantly lower than those of group 1 (vaccinated for first time) or of group 3 (given conjugate vaccine 4 years earlier) (P õ .003 at 7 days and P õ .01 at 28 days). Respective differences between groups 1 and 3 were not significantly different (P ú .05 at both time points).
serum samples obtained at times 0, 7, and 28 days (meningogeometric mean titer of group 2 (previously given the polysaccharide vaccine) was 1/10 lower than the respective titer of coccal A bactericidal assays were not done because of the low IgG responses to the booster). The geometric mean meningogroup 1 (previously unvaccinated subjects) and 1/25 that of group 3 (subjects previously given the conjugate vaccine) (P coccal C bactericidal antibody responses at 0, 7, and 28 days paralleled the respective serum IgG antibody responses. Spe-õ .001). At 28 days, similar respective differences in geometric mean titers were present among the 3 groups (P õ .006). The cifically, at time 0, before the booster, there were no significant differences in the titers of the 3 groups (P Å .5). At day 7, the 1 subject in group 2 showing a bactericidal titer §1:8 after NOTE. For booster injection, all subjects were given 1/50 of usual dose of Menomune (1 mg of each polysaccharide intramuscularly). Group previously given polysaccharide vaccine showed no significant antibody response to booster. Comparing respective geometric mean titers (GMTs) of 3 groups at each time point: Pre, P Å .5; 7 days, P õ .001; 28 days, P Å .005. Pairwise comparisons of GMTs in group previously vaccinated with polysaccharide vs. previously unvaccinated group: 7 days, P Å .01; 28 days, P Å .02. Pairwise comparisons of GMTs in group previously vaccinated with conjugate vaccine vs. previously unvaccinated group: 7 days, P Å .06; 28 days, P Å .24. Pairwise comparisons of % with titers §1:8 in group previously vaccinated with conjugate vs. previously unvaccinated group: 7 days, P õ .02; 28 days, P õ .05 (by x 2 analysis).
/ 9d50$$se05 08-04-98 08:40:22 jinfal UC: J Infect vaccination (table 1) was the same subject with an IgG response patients are likely exposed to low levels of polysaccharide capsule, and their ability to mount protective serum antibody (figure 1). Note also, there was a trend at 7 days for a higher geometric mean titer in group 3 than in group 1 (P Å .06) and responses at this stage might be decisive in affecting the outcome of disease. Of note, vaccinated mice rendered refractory a higher respective percentage of subjects with titers §1:8 (presumed to be protective) (100% vs. 64%; P õ .02).
to certain pneumococcal polysaccharides show increased mortality after experimental challenge with pneumococci of the homologous capsular serotype (reviewed in [15] ), and this inDiscussion creased mortality may be the result of impaired ability to mount serum anticapsular antibody responses on exposure to the enVaccination of older children or adults with plain meningococcal polysaccharide vaccine is highly effective in conferring capsulated bacteria. Given these concerns, until further data are available, use of protection against meningococcal disease caused by serogroups A, C, Y, and W135. However, when this vaccine is used in meningococcal polysaccharide vaccine in low-risk groups needs to take into consideration that any short-or mid-term infants or toddlers, the immunogenicity of the meningococcal C component is poor. Further, vaccination at this early age benefit of vaccination may be offset by the presence of longerterm immunologic refractoriness, which could have adverse induces a refractory state to meningococcal C polysaccharide as defined by impaired serum antibody responses to revaccinaclinical consequences once serum antibody concentrations have declined to sub-protective levels. tion 6 -12 months later. This finding was first shown in immunized infants by Goldschneider et al. [12] in 1973, and subseFinally, the present results indicate that, in contrast to adults vaccinated only with the plain polysaccharide vaccine, adults quently by Gold et al. [13] and Leach et al. [5] . The study by Leach et al., which examined functional serum bactericidal previously vaccinated with meningococcal C conjugate vaccine do not show any evidence of immunologic refractoriness to antibody responses of toddlers in The Gambia boosted with plain polysaccharide vaccine, was particularly striking: Todplain meningococcal C polysaccharide. Indeed, there was an opposite trend: At 7 days, 100% of adults primed with the dlers previously vaccinated at 3 -6 months of age with meningococcal polysaccharide vaccine had, after receipt of a full conjugate and boosted with the 1/50th dose of polysaccharide developed protective meningococcal C bactericidal titers §1:8, dose of meningococcal polysaccharide vaccine 1 year later, meningococcal C bactericidal responses that were 10-fold versus 64% of adults vaccinated with this dose for the first time (P õ .05). A similar difference was present at 28 days lower than those of neighborhood control toddlers vaccinated for the first time.
(P Å .05). Thus, despite similar immunogenicity of the meningococcal conjugate vaccine and polysaccharide vaccine after In a more recent multicenter study in Canada, toddlers immunized at 15 -23 months of age with meningococcal polysacchaprimary vaccination of adults [6] , the conjugate vaccine appears to have induced immunologic memory to meningococcal C ride vaccine also showed evidence of anergy to meningococcal C polysaccharide when given a full dose of vaccine 12 months polysaccharide, which persisted for at least 4 years. Conceivably, the presence of immunologic memory may contribute to later [14] . The present results extend these observations to healthy immunized adults. In the adults, the hyporesponprotection against disease. siveness was detected after revaccination with 1/50 of the usual dose of meningococcal polysaccharide vaccine, a dose chosen as an ''immunologic probe.'' Although the conclusion that the
